Dawn Lundin

Bio:

Dawn is a recognized expert in quality and compliance across pharmaceutical, biotech, and academic environments with 29 years of experience leading teams in risk-based quality management and clinical development strategy. Since 2022, Dawn has been serving in the role of Vice President of Global Quality for Lykos Therapeutics, leveraging expertise from a 20-year tenure in various quality roles for the research division at Merck & Co., and as a member of TransCelerate Biopharma QMS and RBM workstreams. In her spare time, Dawn remains committed to educating the next generation of quality professionals through her role as Director of the Quality Assurance Graduate Program of Study for the University of Pennsylvania. Dawn is fully engaged in innovative approaches to quality by design through partnership, education, and is a champion for risk-based quality management as an enabler to regulatory compliance.